These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26276660)

  • 1. Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina.
    Terzić S; Pilavdžić A; Nadarević Vodenčarević A
    Med Glas (Zenica); 2015 Aug; 12(2):202-5. PubMed ID: 26276660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
    Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
    Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.
    Baudin F; Benzenine E; Mariet AS; Bron AM; Daien V; Korobelnik JF; Quantin C; Creuzot-Garcher C
    JAMA Ophthalmol; 2018 Dec; 136(12):1352-1358. PubMed ID: 30242325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Endophthalmitis Based on Cumulative Number of Anti-VEGF Intravitreal Injections.
    Israilevich RN; Mansour H; Patel SN; Garg SJ; Klufas MA; Yonekawa Y; Regillo CD; Hsu J
    Ophthalmology; 2024 Jun; 131(6):667-673. PubMed ID: 38182029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
    Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
    Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
    Ng DS; Kwok AK; Chan CW; Li WW
    Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway.
    Jørstad ØK; Steffensen LA; Eriksen K; Bragadóttir R; Moe MC
    Acta Ophthalmol; 2020 Dec; 98(8):774-779. PubMed ID: 31264363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
    Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
    J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 20. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.